10:54 AM EDT, 10/29/2024 (MT Newswires) -- Tivic Health Systems ( TIVC ) said Tuesday it has enrolled a first subject in the optimization study for its patent-pending non-invasive vagus nerve stimulation device.

Conducted by The Feinstein Institute of Bioelectronic Medicine, the study aims to determine the optimal device settings, such as frequency and treatment duration for influencing autonomic nervous system function, the company said, adding that the enrollment is anticipated to be completed by early December.

Shares of Tivic Health Systems ( TIVC ) were up 1.7% in recent Tuesday trading.

Price: 0.30, Change: +0.01, Percent Change: +1.69